Sugimoto, Mikio
Kato, Takuma
Tohi, Yoichiro
Shimizu, Yosuke
Matsumoto, Ryuji
Inoue, Takahiro
Takezawa, Yutaka
Masui, Kimihiko
Sasaki, Hiroshi
Hirama, Hiromi
Saito, Shiro
Egawa, Shin
Kamoto, Toshiyuki
Teramukai, Satoshi
Kojima, Shinsuke
Kikuchi, Takashi
Kakehi, Yoshiyuki
Article History
Received: 13 July 2022
Accepted: 29 August 2022
First Online: 14 September 2022
Declarations
:
: This study was conducted following the provisions of the Declaration of Helsinki and the Clinical Trials Act, the Japanese law for the ethical conduct of clinical trials. The ethics review committee of Kagawa University Hospital, TRI, and the individual, institutional review boards of all participating facilities approved this study (trial registration: UMIN000018964). According to the Clinical Trials Act, the clinical trials review board of Kagawa University Hospital also approved and certified this study (trial registration: CRB6180007).Written informed consent was obtained from all individual participants included in this study.
: Not applicable.
: Mikio Sugimoto received a research grant (PI, collaborator or consultant; pending and received grants), speakers bureau/honoraria from Astellas Pharma Inc. Shin Egawa received scholarship donations from Takeda Pharma Ltd., Ono Pharma Ltd., and Bayer Ltd. Toshiyuki Kamoto receives honoraria from AstraZeneca KK, Sanofi KK, and Janssen Ph. KK and received research funding from Takeda Pharma Ltd.